Nonalcoholic fatty liver disease and HFE gene mutations: A Polish study

Table 1 Selected characteristics of patients with NAFLD

	Minimum	Median	Maximum	mean ± SD
Age (yr)	25	48	75	46.56 ± 11.91
Fe (10.56-228.3 μmol/L)	4.12	20.9	68.4	21.4 ± 9.79
Transferrin saturation (< 45%)	7.6	36	206	40.59 ± 30.46
Ferritin (629.2-7999.3 pmol/L)	629.2	5336.6	129 584.4	9714.9 ± 18 409.2
AST (< 38 IU/L)	16	45.5	275	57.44 ± 43.91
ALT (< 41 IU/L)	15	73	281	86.37 ± 57.35
AST/ALT ratio	0.36	0.62	2.43	0.79 ± 0.47
PLT (150-400 × 109/L)	93	218	376	224.98 ± 67.47
Albumin (34-48 g/L)	36.8	46.2	54.8	45.8 ± 4.0
Glycemia (3.89-5.83 mmol/L)	3.44	5.6	11.8	581.7 ± 1.27
BMI (19-25 kg/m2)	21.2	29.05	39.3	29.10 ± 4.17
HOMA (> 1.8)	0.44	4	35.63	7.44 ± 9.25
HBA1c (4.8%-5.9%)	4.99	5.76	9.76	6.20 ± 1.26

NAFLD: Nonalcoholic fatty liver disease; Fe: Iron; AST: Aspartate transaminase; ALT: Alanine transaminase; PLT: Platelet count; BMI: Body mass index; HOMA: Homeostatic model assessment; HBA₁c: Glycated hemoglobin.

Table 2 Comparison of selected clinical data between patients with fatty liver and no/mild and advanced fibrosis

	Fibrosis 0-2 (n = 48)	Fibrosis 3-4 (n = 14)	P value
Age (yr)	45 ± 12	51 ± 11	0.096
BMI (19-25 kg/m2)	28.68 ± 3.85	30.64 ± 5.05	0.135
AST (< 38 IU/L)	51.27 ± 38.75	80.69 ± 55.27	0.091
ALT (< 41 IU/L)	89.10 ± 53.64	75.85 ± 71.39	0.462
AST/ALT ratio	0.65 ± 0.31	1.33 ± 0.55	0.001
PLT (150-400 × 109/L)	231.08 ± 66.51	201.54 ± 68.57	0.161
Glucose (3.89-5.83 mmol/L)	5.36 ± 0.74	7.08 ± 20.5	0.020
HOMA (> 1.8)	6.0 ± 8.4	13.1 ± 10.7	0.144
Fe (10.56-228.28 μmol/L)	19.9 ± 7.32	26.9 ± 15.0	0.028
Ferritin (629.2-7999.3 pmol/L)	742.2 ± 753.9	1934.4 ± 3914.3	0.362
Albumin (34-48 g/L)	4.64 ± 0.38	4.31 ± 0.37	0.017
HBA1c (4.8%-5.9%)	5.92 ± 0.96	7.48 ± 1.78	0.121
Transferrin saturation (< 45%)	38.68 ± 30.88	49.06 ± 28.64	0.361

Table 3 Frequencies of C282Y and H63D HFE gene mutations in patients with NAFLD

HFE gene mutation	Fibrosis 0-2 (n = 48)	Fibrosis 3-4 (n = 14)
C282Y/C282Y	1	0
C282Y/W	1	0
H63D/H63D	3	0
H63D/W	11	3